Bionano Genomics Inc Cash Flow Conversion Efficiency
Bionano Genomics Inc cash flow conversion efficiency. Based on the latest financial reports, Bionano Genomics Inc (BNGO) has a cash flow conversion efficiency ratio of -0.148x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.67 Million) by net assets ($31.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bionano Genomics Inc (2016–2025)
Cash flow conversion efficiency of Bionano Genomics Inc from 2016 to 2025. This chart illustrates how Bionano Genomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Bionano Genomics Inc for real-time trading data and today's change.
Bionano Genomics Inc Cash Flow Conversion Ratio Explained
Bionano Genomics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bionano Genomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bionano Genomics Inc ranked by their cash flow conversion efficiency. Also see Bionano Genomics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vertice Bhd
KLSE:7240
|
0.051x |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
-1.155x |
|
Auking Mining Ltd
AU:AKN
|
-0.199x |
|
123fahrschule SE
DU:123F
|
-0.004x |
|
Schulte-Schlagbaum AG
DU:SSS
|
N/A |
|
Soditech SA
PA:SEC
|
0.053x |
|
Legacy Minerals Holdings Ltd
AU:LGM
|
-0.037x |
|
Rcm Beteiligungs AG
F:RCMN
|
N/A |
Annual Cash Flow Conversion Efficiency for Bionano Genomics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Bionano Genomics Inc from 2016 to 2025. Review BNGO financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.42 Million | $-16.34 Million | -0.368x | +81.12% |
| 2024-12-31 | $35.38 Million | $-68.92 Million | -1.948x | -49.66% |
| 2023-12-31 | $96.16 Million | $-125.18 Million | -1.302x | -160.12% |
| 2022-12-31 | $249.40 Million | $-124.82 Million | -0.500x | -134.57% |
| 2021-12-31 | $337.12 Million | $-71.93 Million | -0.213x | +80.46% |
| 2020-12-31 | $35.08 Million | $-38.31 Million | -1.092x | +86.64% |
| 2019-12-31 | $3.61 Million | $-29.53 Million | -8.172x | -315.36% |
| 2018-12-31 | $10.14 Million | $-19.94 Million | -1.967x | -574.67% |
| 2017-12-31 | $-50.23 Million | $-20.82 Million | 0.414x | -51.92% |
| 2016-12-31 | $-27.26 Million | $-23.50 Million | 0.862x | -- |
About Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simpl… Read more